AbbVie: acquires Capstan Therapeutics for up to $2.1 billion, adding targeted LNP (tLNP) in vivo CAR-T technology to its immunology pipeline. CRISPR Therapeutics: Phase 1 data show LNP-delivered CRISPR candidate CTX310 cuts triglycerides and LDL by up to 82% and 86%, respectively. University of Pennsylvania–Genevant (Nature Nanotechnology): PEG-lipid ratio and phospholipid choice fine-tune mRNA-LNP adjuvanticity, guiding vaccine design. Ludwig-Maximilians-Universität Münch